Available IPD datapackage for study 'A Phase II, Open-label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti−PD-L1 Antibody) Compared With Docetaxel in Patients With Non−Small Cell Lung Cancer After Platinum Failure'

This multicenter, open-label, randomized study will evaluate the efficacy and safety of Atezolizumab compared with docetaxel in participants with advanced or metastatic non-small cell lung cancer after platinum failure. Participants will be randomized to receive either Atezolizumab 1200 milligram (mg) intravenously every 3 weeks or docetaxel 75 milligram per meter square (mg/m^2) intravenously every 3 weeks. Treatment with Atezolizumab may be continued as long as participants are experiencing clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.

本项多中心、开放标签、随机对照试验，旨在评估阿替利珠单抗(Atezolizumab)对比多西他赛(docetaxel)在铂类治疗失败后的晚期或转移性非小细胞肺癌受试者中的疗效与安全性。受试者将被随机分配接受以下两种治疗方案之一：阿替利珠单抗1200毫克(mg)，每3周静脉输注1次；或多西他赛75毫克每平方米(mg/m²)，每3周静脉输注1次。只要研究者评估受试者存在临床获益（即未出现不可接受的毒性，或未出现由疾病进展导致的症状恶化），即可持续接受阿替利珠单抗治疗。